Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-01-13

FDA Approved: ASHLYNA — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)

View source ↗

Summary

The FDA approved a supplemental application for ASHLYNA, a combined oral contraceptive containing levonorgestrel and ethinyl estradiol, manufactured by Glenmark…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ASHLYNA (LEVONORGESTREL AND ETHINYL ESTRADIOL)

Snippet

SUPPL AP for ASHLYNA (LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL)